The Magazine for Sleep Professionals
Thursday, May 7, 2026
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 […]
Although there are more than half a billion individuals worldwide affected by moderate to severe obstructive sleep apnea (OSA), the vast majority still remain undiagnosed and many are untreated.1-2 Healthcare in the United States is facing shortages at every level—and these shortages are projected to increase sharply over the next […]
In previous editions, we’ve talked a lot about how diagnosis is only the first part of the journey with narcolepsy. It’s true that there are many pieces to managing the disorder that follow, but that diagnosis is something we really want to hone in on in this edition. The information […]
Axsome Therapeutics, Inc. a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates (Hetero) resolving patent litigation related to Axsome’s product SUNOSI® (solriamfetol). The litigation, which […]
When it comes to pediatric sleep studies, transcutaneous monitoring plays a crucial role in providing optimal care for young patients. At the Nemours Children’s Hospital Pediatric Sleep Center in Orlando, Florida, CO2 monitoring is integrated into therapist-driven protocols to ensure accurate diagnosis and optimal management of sleep-disordered breathing for pediatric […]
In the field of sleep medicine, obtaining accurate and reliable data is paramount for proper diagnosis and treatment. This is the driving force behind Dymedix Diagnostics, a company that has been at the forefront of developing innovative diagnostic sleep sensors and electrodes for clinical sleep studies. Founded in 2001, Dymedix’s […]
Recent research has elevated the management of obesity in patients with sleep disorders to a prominent position in clinical practice. Obesity has been capturing attention across social media, mainstream news, and even in cultural references such as South Park specials and Jimmy Kimmel’s 2023 Oscars commentary. This heightened focus underscores […]
EnsoData, an innovator in AI solutions in sleep medicine, adds Bobby Cockrill, MBA, as Chief Commercial Officer, (CCO). Cockrill will oversee strategy and execution of sales and marketing functions and continue accelerating EnsoSleep PPG™, EnsoSleep™, RPM, and EnsoTherapy™ adoption across North America. Cockrill comes from Bardy Diagnostics (BDx), where he […]
EnsoData, a leader in healthcare AI technology, is partnering with Advanced Brain Monitoring (ABM) to add position data captured by ABM’s Night Shift sleep positioner into the FDA-cleared EnsoSleep PPG home sleep test (HST). Adding positional data to EnsoSleep PPG offers providers accurate supine AHI severity insights, leading to better […]
Apnimed, Inc., a pharmaceutical company building the industry-leading portfolio of first-in-class oral drug candidates that address the root causes of obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced positive topline results from its pivotal Phase 3 SynAIRgy clinical trial evaluating the efficacy and safety of Apnimed’s lead […]
